Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

Rhea-AI Summary

Cerus Corporation (CERS) will release its fourth quarter and full-year 2023 financial results on March 5, 2024. A conference call and webcast will follow to discuss the financial results and provide a business outlook.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through March 19, 2024.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220312067/en/

Jessica Hanover – Vice President, Corporate Affairs

Cerus Corporation

925-288-6137

Source: Cerus Corporation

When will Cerus Corporation release its fourth quarter and full-year 2023 financial results?

Cerus Corporation will release its fourth quarter and full-year 2023 financial results on Tuesday, March 5, 2024, after the close of the stock market.

What time is the conference call and webcast scheduled for?

The conference call and webcast will be at 4:30 P.M. ET on the same day as the financial results release, March 5, 2024.

Where can participants listen to the live webcast and view the presentation slides?

Participants can access the live webcast and presentation slides on the Investor Relations page of the Cerus website at http://ir.cerus.com.

How long will the replay of the conference call be available?

The replay of the conference call will be available on Cerus' website approximately three hours after the call and will be accessible through March 19, 2024.